{
    "nct_id": "NCT04111458",
    "official_title": "A Phase I Open-label Dose Escalation Trial of BI 1701963 as Monotherapy and in Combination With Trametinib in Patients With KRAS Mutated Advanced or Metastatic Solid Tumours",
    "inclusion_criteria": "Inclusion criteria:\n\nAll parts\n\n* Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in tumour tissue or blood prior to screening\n* At least one target lesion that can be measured per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function\n* Age ≥18 years of age, or over the legal age of consent as required by local legislation.\n* Signed and dated written informed consent in accordance with GCP and local legislation prior to admission to the trial.\n* Women of childbearing potential who are not surgically sterilized must have a negative serum pregnancy test completed during the Screening period\n* Further inclusion criteria apply\n\nMonotherapy and combination therapy dose escalation and monotherapy dose confirmation part\n\n- Documented disease progression despite appropriate prior standard therapies or for whom no standard therapy exists for their tumour type and disease stage\n\nCombination dose confirmation and expansion cohort\n\n* Pathologically confirmed diagnosis of adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.\n* Locally advanced stage IIIb or metastatic stage IV Non-small cell lung cancer (NSCLC)\n* Patients must have received both chemotherapy and immunotherapy\n\nExclusion criteria:\n\nAll parts\n\n* Previous anticancer chemotherapy within 3 weeks of the first administration of trial drug.\n* Previous treatment with RAS, Mitogen-activated protein kinase (MAPK) or Son of sevenless 1 (SOS1) targeting agents\n* Major surgery performed within 4 weeks prior to start of treatment\n* Uncontrolled hypertension, congestive heart failure NYHA classification of ≥3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to start of treatment\n* Left ventricular ejection fraction (LVEF) <50 %\n* Congenital long QT prolongation syndrome\n* Mean resting corrected QT interval (QTcF) >470 msec\n* Leptomeningeal carcinomatosis\n* Presence or history of uncontrolled or symptomatic brain metastases\n* Known pre-existing interstitial lung disease\n* Known active hepatitis B infection (defined as presence of Hep B sAg and/or Hep B Deoxyribonucleic acid (DNA)), active hepatitis C infection (defined as presence of Hep C Ribonucleic acid (RNA))\n* Active infectious disease\n* Any history or presence of uncontrolled gastrointestinal disorders that could affect the intake and/or absorption of the trial drug\n* History of retinal vein occlusion (RVO) or retinal pigment epithelial detachment (RPED)\n* Further exclusion criteria apply\n\nCombination part\n\n- Hypersensitivity to any of the excipients listed in the current Summary of Product Characteristics (SmPC)/Package insert (PI) of trametinib\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}